Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT01620216
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT01594216
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Ruxolitinib in Patients With Breast Cancer
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT01562873
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT01445769
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT01433445
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Study of Ruxolitinib in Pancreatic Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 136
- Registration Number
- NCT01423604
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2019-09-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT01392443
- Locations
- 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT01375140
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT01369498
- Locations
- 🇺🇸
Stanford University Medical center, Stanford, California, United States
🇺🇸Oncology Hematology Care Clinical Trials, Cincinnati, Ohio, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 66
- Registration Number
- NCT01348490
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.